BEIJING — A COVID-19 vaccine candidate developed by the Institute of Microbiology under the Chinese Academy of Sciences has shown to be safe in early-stage trials, suggesting potential for further clinical tests.

The results of phase-1 and phase-2 trials support the safety and immunogenicity of this recombinant subunit vaccine in healthy participants, and no serious adverse events have been found so far, the institute said in a statement on Friday.…

This news comes via ChinaPulse.com, which delivers news, data, analysis, and insights on Chinese business, travel, finance, health, military, investment, and technology.